OBJECTIVE: The purpose of this study was to determine whether estrogen suppresses matrix metalloproteinase-2 and -9 proenzyme expression by fibroblasts that are derived from the supportive connective tissue of the pelvic floor. STUDY DESIGN: A primary fibroblast culture that was developed from a biopsy specimen of the arcus tendineus was treated with interleukin-1 beta (10-15 ng/mL), transforming growth factor-beta 1 (5-15 ng/mL), 17 beta-estradiol (10(-9)-10(-7) mol/L), and Imperial Chemical Industries (ICI) 182 780 (10(-8)-10(-6) mol/L). Cellular and extracellular protein were analyzed by Western blotting and substrate zymography, respectively, for the effect of each treatment on the amount of pro-matrix metalloproteinase-2 and -9 and the membrane type 1 matrix metalloproteinase protein. RESULTS: Both cellular and extracellular pro-matrix metalloproteinase-2 protein were increased by transforming growth factor-beta1 (P =.01) and decreased by estradiol (P <.001) and ICI 182 780 (P =.02 and.002, respectively). Membrane type 1 matrix metalloproteinase was not affected by estradiol, ICI 182 780, interleukin-1 beta, or transforming growth factor-beta 1. Extracellular pro-matrix metalloproteinase-9 was increased by the cytokines interleukin-1 beta (P <.001) and transforming growth factor-beta1 (P <.001) and decreased by estradiol (P <.001) and ICI 182 780 (P <.001). CONCLUSION: The proenzymes of the tissue-degrading matrix metalloproteinases -2 and -9 are decreased by 17-beta estradiol and ICI 182 780.
OBJECTIVE: The purpose of this study was to determine whether estrogen suppresses matrix metalloproteinase-2 and -9 proenzyme expression by fibroblasts that are derived from the supportive connective tissue of the pelvic floor. STUDY DESIGN: A primary fibroblast culture that was developed from a biopsy specimen of the arcus tendineus was treated with interleukin-1 beta (10-15 ng/mL), transforming growth factor-beta 1 (5-15 ng/mL), 17 beta-estradiol (10(-9)-10(-7) mol/L), and Imperial Chemical Industries (ICI) 182 780 (10(-8)-10(-6) mol/L). Cellular and extracellular protein were analyzed by Western blotting and substrate zymography, respectively, for the effect of each treatment on the amount of pro-matrix metalloproteinase-2 and -9 and the membrane type 1 matrix metalloproteinase protein. RESULTS: Both cellular and extracellular pro-matrix metalloproteinase-2 protein were increased by transforming growth factor-beta1 (P =.01) and decreased by estradiol (P <.001) and ICI 182 780 (P =.02 and.002, respectively). Membrane type 1 matrix metalloproteinase was not affected by estradiol, ICI 182 780, interleukin-1 beta, or transforming growth factor-beta 1. Extracellular pro-matrix metalloproteinase-9 was increased by the cytokines interleukin-1 beta (P <.001) and transforming growth factor-beta1 (P <.001) and decreased by estradiol (P <.001) and ICI 182 780 (P <.001). CONCLUSION: The proenzymes of the tissue-degrading matrix metalloproteinases -2 and -9 are decreased by 17-beta estradiol and ICI 182 780.
Authors: Peter G Drewes; Hiromi Yanagisawa; Barry Starcher; Ian Hornstra; Katalin Csiszar; Spyridon I Marinis; Patrick Keller; R Ann Word Journal: Am J Pathol Date: 2007-02 Impact factor: 4.307
Authors: Wenjun Zong; Zegbeh C Jallah; Suzan E Stein; Steven D Abramowitch; Pamela A Moalli Journal: Female Pelvic Med Reconstr Surg Date: 2010-09-01 Impact factor: 2.091
Authors: Sang Wook Bai; Da Jung Chung; Jung Mi Yoon; Jong Seung Shin; Sei Kwang Kim; Ki Hyun Park Journal: Int Urogynecol J Pelvic Floor Dysfunct Date: 2005-05-25
Authors: Marianna Alperin; Steven Abramowitch; May Alarab; Maria Bortolini; Bryan Brown; Lindsey A Burnett; Kathleen A Connell; Margot Damaser; Raffaella de Vita; Caroline E Gargett; Marsha K Guess; Zeliha Guler; Renato Natal Jorge; Robert S Kelley; Mark Kibschull; Kristin Miller; Pamela A Moalli; Indira U Mysorekar; Megan R Routzong; Oksana Shynlova; Carolyn W Swenson; Marrisa A Therriault; Gina M Northington Journal: Int Urogynecol J Date: 2022-06-08 Impact factor: 1.932
Authors: Pamela A Moalli; Kristen M Debes; Leslie A Meyn; Nancy S Howden; Steven D Abramowitch Journal: Am J Obstet Gynecol Date: 2008-04-08 Impact factor: 8.661
Authors: Shokoufeh Mahmoodzadeh; Elke Dworatzek; Stephan Fritschka; Thi Hang Pham; Vera Regitz-Zagrosek Journal: Cardiovasc Res Date: 2009-10-27 Impact factor: 10.787